The document is a regulatory filing containing the transcript of the Q2 & H1FY2027 Earnings Conference Call hosted by the company on Thursday, 12th November, 2026.
The conference call was hosted by Motilal Oswal Financial Services Limited and was moderated by Mr. Tushar Manudhane.
Management participants included Mr. Sandeep Singh (Managing Director), Dr. Amrut Naik (Chief Executive Officer), Mr. Dishant Hitesh Doshi (Deputy Chief Financial Officer), and Mr. Smeett Jain (Head of Investor Relations).
The transcript was submitted to the exchanges on 18th November, 2026, and was stated to be made available on the company's website.
The purpose of the call was to discuss the company's financial results for Q2 FY27, which had been announced earlier that day along with a press release and investor presentation, all filed with the stock exchanges.
The discussion included forward-looking statements and covered the company's performance across its India formulations business, international business (U.S. and non-U.S.), and newer growth platforms (MedTech and biotech).
Financial & Operational Highlights (As Disclosed)
Revenue from Operations: INR 4,520 crores, representing a year-on-year growth of 13.8%.
Biotech Sales (Enzene): INR 70 crores, with a year-on-year degrowth of 35%, attributed to the lumpy nature of the CDMO business.
MedTech Sales (incl. Occlutech): INR 133 crores.
EBITDA: INR 1,025 crores, resulting in an EBITDA margin of 22.5%, a growth of 11.3% year-on-year.
R&D Expenses: 4.3% of revenues.
Profit Before Tax: Grew 7.7% year-on-year.
Net Profit: Saw a degrowth of 11.7%.
Net Cash: Stood at over INR 4,900 crores.
India Business (IQVIA): Grew at 13.8% YoY, in line with the Indian pharmaceutical market (IPM). The acute segment grew 12.1% (IPM acute: 12.3%). The chronic segment grew 22.4% (IPM chronic: 16%), an outperformance of 640 basis points.
International Business: The U.S. business saw a 2% growth, with a 10% volume expansion offset by 16% price erosion. Non-U.S. markets grew 58%, led by Latin America (Colombia, Mexico, Chile) and Australia.
Regulatory Update: Remediation of the Daman facility is progressing, and the company remains engaged with the U.S. FDA regarding its OAI status. The U.S. FDA inspection of the Mandva API facility concluded with no 483s.
Guidance & Outlook (As Disclosed)
EBITDA Margin Guidance for FY27: Maintained at 20%-21%, despite H1 performance being above the range, due to expected dilution from newer businesses (Occlutech and Enzene).
R&D Expense Guidance: Maintained at 4%-4.5% of revenue.
U.S. Business Growth (Constant Currency): Expected to be mid-single digit for FY27.
India Business Growth: Expected to be ~11% for FY27.
Non-U.S. International Business Growth: Expected to be strong double-digit for H2 FY27 and mid-teens for FY28.
New Businesses: Enzene (biotech) is expected to break even in 18-24 months and double in size in four years. MedTech (Occlutech) is expected to break even in a year's time. Combined capex of ~INR 600-700 crores is anticipated over the next 3-4 years for these platforms.
Additional Notes Section
The document is an enclosure to a letter submitted to the stock exchanges, containing the full transcript of the earnings conference call.
The transcript includes a detailed Q&A session with analysts from various brokerages (Nomura, Macquarie, HSBC, Elara Securities, Dolat Capital, Bank of America, etc.).
Key topics discussed in the Q&A included: the slowdown in the trade generics segment in India; the impact of the Daman facility's OAI status on U.S. launches; the launch and outlook for tolvaptan in the U.S.; the financial impact of consolidating Occlutech (goodwill of ~INR 700 cr, identifiable intangibles of ~INR 1,100 cr); and the strategic focus on the chronic portfolio in India.
The company stated that no unpublished price sensitive information (UPSI) was shared during the call.
The transcript concluded with closing comments from the Head of Investor Relations.